New drug cocktail shows promise for tough ovarian cancers
NCT ID NCT03462342
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer, and some had already stopped responding to PARP inhibitors. The trial looked at side effects, tumor response, and how long patients lived without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD6738 (ATR inhibitor) and olaparib (PARP inhibitor)
What this could lead to
If successful, this combination could offer a new treatment option for women with recurrent ovarian cancer, potentially slowing disease progression even after other treatments have failed.
What could go wrong
This is a Phase 2 trial with 123 participants, so results are still early. The combination may cause significant side effects, and not all patients may respond, especially those resistant to PARP inhibitors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287, United States